AUAUniversity

Prostate Cancer Update (2024): Expert Guidance for Urologists

CME Available: https://auau.auanet.org/node/41868

Acknowledgements

Support provided by independent educational grants from:

Astellas

Lantheus Medical Imaging

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Learning Objectives

At the conclusion of this activity, the learner will:

1. Align their practice with current AUA Guidelines (and recent amendments) pertaining to Screening, Diagnosis, and Management of Prostate Cancer.

2. Determine appropriate use of biomarker testing as it relates to diagnosis and therapy.

3. Analyze the role of imaging and types of imaging that aid in staging patients with prostate cancer.

4. Implement appropriate treatment paradigms for metastatic prostate cancer including treatment intensification.

5. Discuss the role of genetic and molecular profiling in the personalization of prostate cancer treatment plans.

Treatment Intensification in Metastatic HSPC

CME Available: https://auau.auanet.org/node/41733

ACKNOWLEDGEMENTS:

Support provided by independent educational grants from: 

Lantheus Medical Imaging

Novartis Pharmaceuticals Corporation

LEARNING OBJECTIVES:

At the conclusion of this activity, participants will be able to:

1. Explain the rationale behind treatment intensification in metastatic hormone sensitive prostate cancer (mHSPC), based on its pathophysiology. 

2. Analyze the rationale and clinical evidence supporting treatment intensification in mHSPC, including potential benefits and risks. 

3. Select appropriate patients for treatment intensification, considering factors such as disease burden, patient comorbidities, and individual risk profiles.

Appropriate Use of Genetic Testing (who, what, when and how?)

CME Available: https://auau.auanet.org/node/41734

ACKNOWLEDGEMENTS:

Support provided by independent educational grants from: 

Lantheus Medical Imaging

Novartis Pharmaceuticals Corporation

LEARNING OBJECTIVES:

At the conclusion of this activity, participants will be able to:

1. Identify the patient populations that should be considered for genetic testing in prostate cancer, based on family history, personal risk factors, and clinical indications.

2. Integrate genetic testing into clinical practice for prostate cancer, including developing workflows, referral processes, and multidisciplinary collaboration.

3. Utilize genetic test results to inform personalized treatment plans for prostate cancer patients, including targeted therapies and risk reducing strategies.

Sequencing Of Agents

CME Available: https://auau.auanet.org/node/41735

ACKNOWLEDGEMENTS:

Support provided by independent educational grants from:

Lantheus Medical Imaging

Novartis Pharmaceuticals Corporation

LEARNING OBJECTIVES:

At the conclusion of this activity, participants will be able to:

1. Review the latest evidence and clinical guidelines that inform the sequencing of therapeutic agents in metastatic prostate cancer, including data from key clinical trials.

3. Implement strategies for managing and overcoming resistance to therapy in metastatic prostate cancer, considering the role of sequencing in delaying resistance.

4. Apply best practices for monitoring treatment response and disease progression in patients undergoing therapy, and adjust sequencing strategies based on these observations.

Urologic Oncology: Genetics And Genomics

AUA Urology Core Curriculum: auau.auanet.org/core

Host: Jay D. Raman, MD, FACS, FRCS(Glasg)

Guest: Hong Truong, MD, MS

Outline:

Segment 1: Genetics 101 – How Genes Influence Cancer Risk

Segment 2: Genetic Risk Assessment

Segment 3: Genetics of Kidney Cancer

Segment 4: Genetics of Upper Tract Cancer

Segment 5: Genetics of Prostate Cancer

Biomarkers and Molecular Imaging for Prostate Cancer

CME Available: https://auau.auanet.org/node/41727

ACKNOWLEDGEMENTS:

Support provided by independent educational grants from: 

Lantheus Medical Imaging

Novartis Pharmaceuticals Corporation

LEARNING OBJECTIVES:

At the conclusion of this activity, participants will be able to:

1. Explain the principles of molecular imaging and its application in prostate cancer, including techniques such as PET, MRI, and novel radiotracers.

2. Evaluate recent advances in molecular imaging technologies and their role in improving the accuracy of prostate cancer diagnosis, staging, and treatment monitoring.

3. Define and classify different types of biomarkers relevant to prostate cancer, including diagnostic, prognostic, and predictive biomarkers.

Kidney Cancer & SBRT in the Management of RCC

AUA Urology Core Curriculum: auau.auanet.org/core

Host: Jay D. Raman, MD, FACS, FRCS(Glasg)

Guest: Daniel Shapiro, MD

Outline:

Segment 1: History of radiation therapy in renal cell carcinoma

Segment 2: Radiation use in the setting of primary kidney tumors

Segment 3: Radiation use for locally advanced tumors including tumor thrombi

Segment 4: Radiation therapy for metastatic disease

Segment 5: Limitations of radiation therapy and selecting patients for radiation therapy

Pediatric Urology: Differences of Sex Development

AUA Urology Core Curriculum: auau.auanet.org/core

Host: Jay D. Raman, MD, FACS, FRCS(Glasg)

Guest: Emilie Johnson, MD, MPH, FACS, FAAP

Outline:

Segment 1: DSD Nomenclature – Words Matter!

Segment 2: Multidisciplinary Care Model

Segment 3: Example Conditions

Segment 4: Approach to Prenatal and Early Postnatal Care

Segment 5: Gonadal Management – also evolving

How to use Prostate-Specific Membrane Antigen-Positron Emission Tomography/CT in the Management of Relapsing Prostate Cancer Patients following Local Therapy with Curative Intent

CME Available: https://auau.auanet.org/node/41124

At the conclusion of this activity, participants will be able to:

1. Identify the clinical scenario in which PSMA PET/CT is most helpful to identify the localization and extent of locoregional or systemic metastatic disease.

2. Identify the pitfalls of false-positive and false-negative PSMA PET/CT findings.

3. Apply the findings of PSMA PET/CT for the best individual therapeutic approach.

4. Identify patients with radiorecurrent organ-confined prostate cancer.

5. Identify those patients who are candidates for local therapy of oligometastatic disease in relapsing prostate cancer.

ACKNOWLEDGEMENTS

This educational activity is supported by independent educational grants from:

Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.

The Changing Face of Advanced Prostate Cancer 2024

CME Available: https://auau.auanet.org/node/41136

At the conclusion of this activity, participants will be able to:

1. Identify and treat a patient with newly diagnosed M1 prostate cancer with androgen deprivation therapy plus be able to offer novel ADT. Furthermore, recognize high-volume new M1 prostate cancer so as to be able to refer to a genitourinary medical oncologist for chemotherapy if necessary.

2. Diagnose M0 CRPC, and be able to educate patients about using novel oral androgen receptor inhibitors added to traditional androgen deprivation therapy as a way to improve their patent's overall and radiographic progression-free survival. Furthermore, understand the differences between these novel oral agents and educate patients about side effects and toxicities. Finally, understand the role or lack of role of prostate-specific membrane antigen PET in working up this disease state.

3. Apply the latest phase III randomized controlled trial results for new therapies in M1 CRPC, and be able to educate their patients on treatment options and work on a multidisciplinary team caring for this disease state of far advanced prostate cancer.

4. Identify that advanced prostate cancer is a complex group of disease states with a rapidly changing therapeutic landscape, and for providers and teams to embrace the multidisciplinary nature of care for our patients.

5. Identify the molecular and molecular genetic underpinnings of advanced prostate cancer and recognize the future will be based on a more personalized therapy landscape including PARP inhibition, immune checkpoint agents and novel androgen receptor-targeted agents emerging in 2024.

ACKNOWLEDGEMENTS

This educational activity is supported by independent educational grants from:

Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.